Section 12: Cardiovascular Drugs
12.1 ANTIANGINAL DRUGS
¤atenolol tablet, 50 mg, 100 mg
glyceryl trinitrate tablet (sublingual), 500 µg
¤isosorbide dinitrate tablet (sublingual), 5 mg
¤verapamil (10) tablet, 40 mg, 80 mg
(hydrochloride)
12.2 ANTIARRHYTHMIC DRUGS
¤atenolol tablet, 50 mg, 100 mg
digoxin (4, 11) tablet, 62.5 µg, 250 µg
oral solution, 50 µg/ml
injection, 250 µg/ml
in 2-ml ampoule
lidocaine injection, 20 mg
(hydrochloride)/ml
in 5-ml ampoule
verapamil (8, 10) tablet, 40 mg,
80 mg (hydrochloride)
injection, 2.5 mg
(hydrochloride)/ml
in 2-ml ampoule
Complementary drugs
epinephrine (C) injection, 1 mg
(as hydrochloride)/ml
isoprenaline (C) injection, 20 µg
(hydrochloride)/ml
¤procainamide (B) tablet, 250 mg,
500 mg (hydrochloride)
injection, 100 mg
(hydrochloride)/ml
in 10-ml ampoule
¤quinidine (A) (7) tablet, 200 mg (sulfate)
12.3 ANTIHYPERTENSIVE DRUGS
¤atenolol tablet, 50 mg, 100 mg
¤captopril scored tablet, 25 mg
¤hydralazine tablet, 25 mg, 50 mg
(hydrochloride)
powder for injection, 20 mg
(hydrochloride) in ampoule
¤hydrochlorothiazide scored tablet, 25 mg
methyldopa (7) tablet, 250 mg
¤nifedipine (10) sustained-release formulations
,
tablet, 10 mg
¤reserpine tablet, 100 µg, 250 µg
injection, 1 mg in 1-ml ampoule
Complementary drugs
prazosin tablet, 500 µg, 1 mg (mesilate)
¤sodium nitroprusside powder for infusion,
(C) (2, 8) 50 mg in ampoule
12.4 DRUGS USED IN HEART FAILURE
¤captopril scored tablet, 25 mg
digoxin (4, 11) tablet, 62.5 µg, 250 µg
oral solution, 50 µg/ml
injection, 250 µg/ml in 2-ml ampoule
dopamine injection, 40 mg
(hydrochloride)/ml in 5-ml vial
¤hydrochlorothiazide tablet, 25 mg, 50 mg
12.5 ANTITHROMBOTIC DRUGS
acetylsalicylic acid tablet, 100 mg
Complementary drug
streptokinase (C) powder for injection,
100 000 IU, 750 000 IU in vial
¤ Example of a therapeutic group. Various drugs can serve as
alternatives.
1 All plasma fractions should comply with the Requirements
for the Collection, Processing and Quality Control of Blood, Blood
Components and Plasma Derivatives (Revised 1992). WHO
Technical Report Series, No. 840, 1994, Annex 2.
Essential Drugs
12.6 LIPID-LOWERING AGENTS
The WHO Expert Committee on Essential Drugs recognizes
the value of lipid-lowering drugs in treating patients
with hyperlipidaemia. Beta-hydroxy-beta-methylglutarylcoenzyme
A (HMG CoA) reductase inhibitors, often referred
to as "statins", are potent and effective lipidlowering
drugs with a good tolerability profile. Several of
these drugs have been shown to reduce the incidence of
fatal and non-fatal myocardial infarction, stroke and
mortality
(all causes), as well as the need for coronary bypass
surgery. All remain very costly but may be costeffective
for secondary prevention of cardiovascular disease
as well as for primary prevention in some very highrisk
patients. Since no single drug has been shown to be
significantly more effective or less expensive than others
in the group, none is included in the model list; the choice
of drug for use in patients at highest risk should be
decided at national level.
|